Compare Five9 Inc (FIVN) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five9 Inc vs 10X Genomics Inc — how do they compare? Five9 Inc trades at $35.96 (market cap $2.63B), while 10X Genomics Inc trades at $81.19 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 3.8× Five9 Inc's market cap, and 10X Genomics Inc is more actively traded (5,657,286 versus 1,864,393). Which is the better fit depends on your goals — on Pluang, investors hold Five9 Inc for 72 Days and 10X Genomics Inc for 91 Days on average.
| FIVN | TXG | |
|---|---|---|
Market Cap | $2.63B | $10.07B |
Volume | 1,864,393 | 5,657,286 |
Sector | Technology | Health |
52-Week High | $38.65 | $97.74 |
52-Week Low | $13.61 | $11.48 |
Typical Hold Time | 72 Days | 91 Days |
Enterprise Value | $2.78B | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five9 (FIVN) trades at $35.10, up 3.91% with strong technical momentum near recent highs. The company shows accelerating revenue growth, reaching $1.15B in 2025 with improving profitability (net margin 4.94%). Recent quarters have consistently beaten EPS estimates, while AI revenue surged 78% YoY to $39M in Q2 2026. Analyst sentiment remains bullish with 61% buy ratings and a $34 consensus target.
Outlook remains positive driven by AI contact center adoption and subscription growth, though high valuation multiples (P/E 51.7) and insider selling present near-term risks. The stock's technical setup suggests continued upside if it maintains above $34 support, but investors should monitor debt levels and competitive pressures in the CCaaS space.
10x Genomics (TXG) trades at $82.37, up 8.24% over 24 hours, with a bearish technical signal and mixed analyst sentiment. The company reported a net loss of $43.54M in 2025, but revenue grew to $642.82M, and it has beaten EPS estimates for three consecutive quarters. Recent news highlights strong demand for its Atera platform and a patent victory, though profitability remains a challenge.
The outlook is cautiously optimistic, with growth potential from new product launches and spatial biology demand, but risks include persistent losses, high valuation multiples, and competitive pressures. The consensus price target is $74.30, below the current price, suggesting limited near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
